Table 2 Epidemiological data a
From: Pirfenidone gel in patients with localized scleroderma: a phase II study
Patient | Sex | Age (yr) | Time of evolution (yr) | Previous treatment | Type of scleroderma | Size of smallest lesion (cm 2 ) | Size of largest lesion (cm 2 ) | Affected segments |
|---|---|---|---|---|---|---|---|---|
1 | F | 47 | 10 | Yes | Linear | 10.5 | 97.5 | 1 |
2 | F | 24 | 1.5 | No | Linear | 1.5 | 17.5 | 1 |
3 | F | 77 | 3 | Yes | Generalized | 1 | 412.5 | 6 |
4 | F | 66 | 6 | Yes | Generalized | 2 | 255 | 5 |
5 | F | 54 | 3 | Yes | Generalized | 31.5 | 448 | 3 |
6 | F | 29 | 3 | Yes | Circumscribed | 360 | 765 | 2 |
7 | F | 21 | 10 | Yes | Circumscribed | 45 | 52.2 | 1 |
8 | M | 31 | 8 | No | Circumscribed | 0.48 | 7 | 1 |
9 | M | 39 | 3 | Yes | Generalized | 0.25 | 136 | 13 |
10 | F | 46 | 2 | Yes | Circumscribed | 12 | 22.5 | 1 |
11 | M | 51 | <1 | No | Generalized | 1 | 36 | 3 |
12 | F | 48 | 4 | No | Generalized | 6 | 189 | 2 |
Mean | NA | 46.5 | 3 | NA | NA | 4 | 116.75 | 2 |
Maximum | NA | 77 | 10 | NA | NA | 360 | 765 | 13 |
Minimum | NA | 21 | 1.5 | NA | NA | 0.25 | 7 | 1 |